Excellent
Mostly Aligned
Patient Risk:
Low
Summary
Both AI statements specifically describe the REMICADE induction schedule and number of infusions; however, the provided label excerpts do not contain dosing/administration schedule information to verify these claims from the supplied text.
Category Scores
Accurate Statements
Unsupported Statements
The induction phase for Remicade is typically 4 infusions total.
Not supported or refuted by the supplied FDA label excerpts (sections 5.1, 5.2, 6.1, 8.4) because none include the induction dosing schedule or total induction infusions.
Remicade induction infusions are given at weeks 0, 2, 6, and 14.
Not supported or refuted by the supplied FDA label excerpts because none include the induction dosing schedule or timing (weeks 0, 2, 6, and 14).
Contradictions
Important Omissions
Verification of the induction dosing schedule (weeks and number of infusions) from the actual FDA-approved prescribing information sections covering Dosage and Administration (not provided in the prompt).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No contradiction to provided label excerpts and the statements concern dosing schedule only; however, dosing details were not verifiable from the supplied excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Label excerpt set provided does not include the Dosage and Administration section needed to verify the induction schedule claims.
Suggested Improvement
Provide the FDA label excerpts from the Dosage and Administration section (e.g., the portion describing induction dosing/timing) or the exact label text covering the induction regimen so the schedule (number of infusions and weeks) can be confirmed.